The first offices of OvaScience, in East Cambridge, didn’t have the company’s name on the door. Somehow, says chief executive Michelle Dipp, women still managed to find the small biotech company and show up to ask questions. Their motivation: having a baby.
OvaScience is developing a treatment to improve the odds for women to get pregnant through in vitro fertilization, or IVF. Each day, says Dipp, she receives at least 10 e-mails from women who want to participate in the company’s first clinical trials.